RVL Pharmaceuticals plc
NASDAQ: RVLP0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Brian A. Markison
- Employees
- 125
- Headquarters
- Bridgewater, United States
- IPO year
- 2018
- Market cap
- $3.1M
- Website
- https://www.rvlpharma.com
Loading RVLP…
Loading profile data…Frequently asked questions about RVLP
What does RVL Pharmaceuticals plc (RVLP) do?
RVL Pharmaceuticals plc operates as a specialized pharmaceutical firm, concentrating on the creation and commercialization of medicinal products. These offerings target patient populations with unmet needs within the fields of ocular health and medical aesthetics across the United States, Argentina, and Hungary. Among its key commercialized prod...
Where does RVLP trade?
RVL Pharmaceuticals plc (RVLP) trades on the NASDAQ Global Select.
What sector is RVLP in?
RVL Pharmaceuticals plc (RVLP) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of RVL Pharmaceuticals plc?
Brian A. Markison is the chief executive officer of RVL Pharmaceuticals plc (RVLP).
Where is RVL Pharmaceuticals plc headquartered?
RVL Pharmaceuticals plc is headquartered in United States.
Does RVLP pay a dividend?
RVL Pharmaceuticals plc (RVLP) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did RVLP go public?
RVL Pharmaceuticals plc (RVLP) completed its initial public offering in 2018.